In response to a question as to whether the type of incision was an issue regarding SSI, Dr. Bandyk said: "It’s the patient that’s producing the infection, and certain patient characteristics, so it isn’t necessarily how we’re closing, which way we are putting the incision ... So don’t blame yourself for every surgical site infection. It’s the patient factors that are operative in many of these cases. Of almost all of our infections that occurred, two-thirds came from the MRSA-colonized patient," he said.
Dr. Bandyk reported being on the speakers bureau and having received funding from Cubist Pharmaceuticals, the manufacturer of daptomycin (Cubicin).